Periprocedural Management of the Chronically Anticoagulated Patient: Critical Pathways for Bridging Therapy

Critical Pathways in Cardiology

Volumn 2, Issue 2, 2003, Pages 96-103

  Piazza, Gregory ^a   Goldhaber, Samuel Z ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anticoagulant; Bridging therapy; Heparin; Low molecular weight heparin; Management

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL PATHWAY; DOSE CALCULATION; DRUG COST; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HEMATOMA; HUMAN; LONG TERM CARE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PRIORITY JOURNAL; PROPHYLAXIS; THROMBOEMBOLISM;

EID: 0142228194     PISSN: 1535282X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hpc.0000077042.02114.15     Document Type: Article

References (18)

1. Heit J. Perioperative management of the chronically anticoagulated patient. J Thromb Thrombolysis. 2001;12:81-87.
2. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med. 1997;336:1506-1511.
3. Ansell J, Hirsh J, Dalen J, et al. Managing oral anticoagulant therapy. Chest 2001;119:22S-38S.
4. Topol E, Casele H, Elkayem U, et al. Anticoagulation and enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Clin Cardiol Consensus Rep. 2002;3(9):1-20.
5. Hirsch DR, Lee TH, Morrison RB, et al. Shortened hospitalization by means of adjusted-dose subcutaneous heparin for deep venous thrombosis. Am Heart J. 1996;131:276-280.
6. Hirsh J, Raschke R, Warkentin TE, et al. Heparin and low-molecular-weight heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998;114:489S-510S.
7. Hull RD, Pineo GF. Therapeutic use of low molecular weight heparins: knowledge to date and their application to therapy. Semin Thromb Hemost. 1994;20:339-344.
8. Simonneau G, Hervé S, Charbonnier B, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. N Engl J Med. 1997;337:663-669.
9. Montalescot G, Polle V, Collet J, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation. 2000;101:1083-1086.
10. Johnson J, Turpie AGG. Temporary discontinuation of oral anticoagulants: role of low molecular weight heparin (dalteparin) [abstract]. Circulation. 2000;102(suppl 18):II-826.
11. Omran H, Hammerstingl C, Schmidt H, et al. A prospective and randomized comparison of low molecular weight heparin and unfractionated heparin in chronically anticoagulated patients prior to cardiac catheterization [abstract]. J Am Coll Cardiol. 2002;39(suppl A):234A.
12. Galla JM, Fuhs BE. Outpatient anticoagulation protocol for mechanical valve recipients undergoing non-cardiac surgery [abstract]. J Am Coll Cardiol. 2000;135(suppl A):531A.
13. Tsilimingras KV, Grasso-Correnti N, Fanikos J, et al. Initiation of anticoagulation after cardiac surgery: a prospective cohort study of efficacy, safety, and cost with low molecular weight heparin bridging in lieu of continuous intravenous unfractionated heparin [abstract]. J Am Coll Cardiol. 2002;39(suppl A):428A.
14. Amorosi S, Fanikos J, Tsilimingras K, et al. "Bridging therapy" during temporary interruption of chronic anticoagulation is less costly with low-molecular weight heparin than unfractionated heparin [abstract]. Circulation. 2002;106:II-758.
15. Heit J, Mohr D, Silverstein M, et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism. Arch Intern Med. 2000;160:761-768.
16. Gelfand EV, Piazza G, Goldhaber SZ. Venous thromboembolism guidebook. Crit Pathways Cardiol. 2002;1:26-43.
17. Prandoni P, Lensing A, Cogo A, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1-7.
18. Grasso-Correnti N, Goldser RC, Goldhaber SZ. The critical pathways of an anticoagulation service. Critical Pathways in Cardiology. 2003;2:41-45.